Nanjing Vazyme Biotech (688105) Stock Overview
Offers technology solutions for life science, biomedicine, and in vitro diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
688105 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nanjing Vazyme Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.61 |
| 52 Week High | CN¥20.59 |
| 52 Week Low | CN¥12.89 |
| Beta | 0.70 |
| 1 Month Change | -15.71% |
| 3 Month Change | -12.15% |
| 1 Year Change | -22.33% |
| 3 Year Change | -44.43% |
| 5 Year Change | n/a |
| Change since IPO | -79.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688105 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.4% | -6.0% | -2.1% |
| 1Y | -22.3% | -25.0% | 28.0% |
Return vs Industry: 688105 exceeded the CN Biotechs industry which returned -25% over the past year.
Return vs Market: 688105 underperformed the CN Market which returned 28% over the past year.
Price Volatility
| 688105 volatility | |
|---|---|
| 688105 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.4% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688105 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688105's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 3,002 | Lin Cao | www.vazyme.com |
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions.
Nanjing Vazyme Biotech Co., Ltd Fundamentals Summary
| 688105 fundamental statistics | |
|---|---|
| Market cap | CN¥7.04b |
| Earnings (TTM) | -CN¥14.34m |
| Revenue (TTM) | CN¥1.41b |
Is 688105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688105 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.41b |
| Cost of Revenue | CN¥463.35m |
| Gross Profit | CN¥950.20m |
| Other Expenses | CN¥964.54m |
| Earnings | -CN¥14.34m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 67.22% |
| Net Profit Margin | -1.01% |
| Debt/Equity Ratio | 22.6% |
How did 688105 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 01:02 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanjing Vazyme Biotech Co., Ltd is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |